Zusammenfassung
Endokrine Therapien spielen eine wichtige Rolle in der Behandlung des hormonsensitiven Mammakarzinoms. Dabei rücken die Aromatasehemmer der dritten Generation aufgrund ihrer hohen antitumorösen Potenz und guten Verträglichkeit zunehmend in den Vordergrund. Aufgrund der aktuellen Datenlage stellen Letrozol und Anastrozol nach ihrer Zulassung jetzt reale Alternativen zum bisherigen Standard Tamoxifen in der First-line-Therapie des metastasierten Mammakazinoms dar. Erste Ergebnisse zu den Studien mit Letrozol, Anastrozol und Exemestan in der neoadjuvanten und adjuvanten Situation liegen bereits vor oder werden in Kürze erwartet. In Abhängigkeit von diesen Studien sollte der adjuvante Einsatz der Aromataseinhibitoren bei der postmenopausalen hormonrezeptorpositiven Patientin abschließend definiert werden.
Abstract
Endocrine therapy is a major part of the management of patients with hormone-sensitive breast cancer. The antitumor activity and good tolerability of the third-generation aromatase inhibitors make them an attractive alternative to tamoxifen. Several well conducted randomized trials led to the regulatory approval of letrozole and anastrozole for the first-line treatment of metastatic breast cancer. Multiple ongoing clinical trials are evaluating letrozole, anastrozole and exemestane in the adjuvant and neoadjuvant settings. The results of these trails will determine the role of aromatase inhibitors, alone or sequentially with tamoxifen, in the adjuvant treatment of postmenopausal women with hormone-sensitive breast cancer.
Literatur
-
1
Boccardo F, Rubagotti A, Amoroso D, Mesiti M, Gallo L, Farris A, Cruciani G. et al .
Tamoxifen vs. aminoglutethimide in breast cancer patients previously treated with adjuvant tamoxifen. Preliminary results of a multicentric comparative study.
Proc ASCO.
2000;
71
abstract 273
-
2
Bonneterre J, Thürlimann B, Robertson J F, Krzakowski M, Mauriac L, Koralewski P. et al .
Anastrozole versus tamoxifen as first-line therapy for advanced breast cancer in 668 postmenopausal women: Results of the Tamoxifen or Arimidex Randomized Group (TARGET) efficacy and tolerability study.
J Clin Oncol.
2000;
18
3748-3757
-
3
Buchanan R B, Blamey R W, Durrant K R, Howell A, Paterson A G, Preece P E. et al .
A randomized comparison of tamoxifen with surgical oophorectomy in premenopausal patients with advanced breast cancer.
J Clin Oncol.
1986;
4
1326-1330
-
4
Buzdar A, Nabholtz J M, Robertson J F, Thürliman B, Bonneterre J, von Euler M.
Anastrozole (Arimidex versus tamoxifen as first-line therapy for advanced breast cancer in postmenopausal women - combined analysis from two identically designed multicenter trials.
Proc ASCO.
2000;
19 (154 a)
abstr 609d
-
5
Buzdar A U, Jonat W, Howell A, Jones S E, Blomqvist C P, Vogel C L. et al .
Anastrozole versus megestrolacetate in the treatment of postmenopausal women with advanced breast carcinoma: results of a survival update based on the combined analysis of data from two mature phase III trials.
Cancer.
1998;
83
1142-1152
-
6
Dirix L Y, Piccart M J, Lohrisch C, Beex L. et al .
Efficacy of and tolerance to Exemestane versus Tamoxifen in 1st-line hormone therapy of postmenopausal metastatic breast cancer patients: A European Organisation for the Research and Treatment of Cancer phase-II trial with Pharmacia and Upjohn.
Proc ASCO.
2001;
20
abstr. 114
-
7
Dixon M J, Love C, Tucker S.
Letrozol as primary medical therapy for local advanced and large operable breast cancer.
Breast Cancer Res Treat.
1997;
46
abstr 213
-
8
Dixon M J, Renshaw L, Bellamy C, Cameron D A, Miller W R.
Arimidex as neoadjuvant therapy causes large reductions in tumor volume in postmenopausal women with large operable breast cancer.
Proc ASCO.
1999;
92
abstr 345
-
9
Dombernowsky P, Smith I, Falkson G, Leonard R, Panasci L, Bellmunt J. et al .
Letrozole, a new oral aromatase inhibitor for advanced breast cancer: double-blind randomized trial showing a dose effect and improved efficacy and tolerability compared with megestrol acetate.
J Clin Oncol.
1998;
16
453-461
-
10
Dowsett M, Coobes R C.
Second generation aromatase inhibitors - 4-hydroxyandrostenedione.
Breast Cancer Res Treat.
1994;
30
81-87
-
11
EBCTCG .
Tamoxifen for early breast cancer: an overview of the randomised trials.
Lancet.
1998;
351
1451-1467
-
12
Ellis M, Coop A, Baljit S, Mauriac L, Llombert-Cussac A, Jänicke F, Miller W R. et al .
Letrozole is more effective neoadjuvant endocrine therapy than tamoxifen for ErbB-1 and/or ErbB-2 positive, estrogen receptor-positive primary breast cancer: evidence from a phase III randomized trial.
J Clin Oncol.
2001;
19
3808-3816
-
13
Fisher B, Dignam J, Bryant J, Wolmark N.
Five versus more than five years of tamoxifen for lymph node-negative breast cancer: updated findings from the National Surgical Adjuvant Breast and Bowel Project B-14 randomized trial.
J Natl Cancer Inst.
2001;
93
684-690
-
14
Friedrichs K, Hölzel F, Jänicke F.
Wirkungsweise und Stellenwert der neuen Aromatasehemmer in der Therapie des Mammakarzinoms.
Geburtsh Frauenheilk.
1999;
59
245-254
-
15
Gershanovich M, Chaudri H A, Campos D, Lurie H, Bonaventura A, Jeffrey M. et al .
Letrozole, a new oral aromatase inhibitor: Randomised trial comparing 2. 5 mg daily, 0. 5 mg daily and aminoglutethimide in postmenopausal women with advanced breast cancer.
Ann Oncol.
1998;
9
639-645
-
16
Kaufmann M, Bajetta E, Dirix L Y, Fein L E, Jones S E, Zilembo N. et al .
Exemestane is superior to megestrol acetate after tamoxifen failure in postmenopausal women with breast cancer: Results of a phase III randomized double-blind trial.
J Clin Oncol.
2000;
18
1399-1411
-
17
Klijn J G, Beex L, Mauriac L, Zijl J A, Veyret C, Wildiers J. et al .
Combined treatment with buserelin and tamoxifen in premenopausal metastatic breast cancer: a randomized study.
J Natl Cancer Inst.
2000;
92
903-911
-
18
Locker G Y.
Hormonal therapy of breast cancer.
Cancer Treat Rev.
1998;
24
221-240
-
19
Lonning P E, Bajetta E, Murray R, Tubiana-Hulin M, Eisenberg P D, Mickiewicz E. et al .
Activity of exemestane in metastatic breast cancer after failure of nonsteroidal aromatase inhibitors: A phase II trial.
J Clin Oncol.
2000;
18
2234-2244
-
20
Milla-Santos A, Milla L, Rallo L, Solano V.
Anastrozole vs. Tamoxifen in hormon dependent advanced breast cancer. A phase II randomized trial.
Breast Cancer Res Treat.
2000;
64
abstr 173
-
21
Mouridsen H, Gershanovich M, Sun Y. et al .
Superior efficacy of letrozole versus tamoxifen as first-line therapy for postmenopausal women with advanced breast cancer: results of a phase III study of the international letrozole breast cancer group.
J Clin Oncol.
2001;
19
2596-2606
-
22
Nabholtz J M, Bonneterre J, Buzdar A, Robertson J FR, Thürlimann B, Steinberg M, Webster A, von Euler M.
Is anastrozole superior to tamoxifen as first-line therapy for advanced breast cancer?.
J Clin Oncol.
2001;
19
2580-2582
-
23
Nabholtz J M, Buzdar A, Pollak M, Harwin W, Burton G, Mangalik A. et al .
Anastrozole is superior to tamoxifen as first-line therapy for advanced breast cancer in postmenopausal women: Results of a North American multicenter randomized trial.
J Clin Oncol.
2000;
18
3758-3767
-
24
Osborne C K.
Aromatase inhibitors in relation to other forms of endocrine therapy for breast cancer.
Endocrine-Related Cancer,.
1999;
6
271-276
-
25
Päpke S, Apffelstaedt J, Eremin J. et al .
Neoadjuvant treatment of postmenopausal breast cancer patients with letrozole (Femara®): a randomized study versus tamoxifen.
Eur J Cancer.
2000;
36
a 179
-
26
Robertson J F, Howell A, Buzdar A, von Euler M, Lee D.
Static disease on anastrozole provides similar benefit as objective response in patients with advanced breast cancer.
Breast Cancer Res Treat.
1999;
58
157-162
-
27
Thürlimann B, Robertson J FR, Bonneterre J.
Efficacy of tamoxifen following arimidex (anastrozole) as first-line treatment for advanced breast cancer in postmenopausal women.
Breast Cancer Res Treat.
2000;
64
abstr 162
Dr. J. Huober
Univ.-Frauenklinik
Schleichstraße 4
72076 Tübingen
eMail: jens.huober@med.uni-tuebingen.de
